Explore

Rapid Read Rapid Read
Genentech's Lunsumio Shows Promise in Lymphoma Treatment

Genentech's Lunsumio Shows Promise in Lymphoma Treatment

Genentech has presented new data on Lunsumio, a bispecific antibody, showing its potential in treating indolent and aggressive lymphomas. The data, presented at the American Society of Hematology Annual Meeting, highlights Lunsumio's efficacy in combination with other drugs for relapsed or refractory follicular lymphoma and large B-cell lymphoma. The studies indicate that Lunsumio could offer improved outcomes and prolonged remission for patients, potentially reducing the need for conventional chemotherapy.
Rapid Read Rapid Read
CARsgen Presents Promising Data on BCMA CAR-T Therapy for Multiple Myeloma at ASH Meeting

CARsgen Presents Promising Data on BCMA CAR-T Therapy for Multiple Myeloma at ASH Meeting

CARsgen Therapeutics Holdings Limited has announced promising clinical data for its allogeneic BCMA-targeted CAR T-cell therapy, CT0596, at the 2025 American Society of Hematology (ASH) Annual Meeting. The study involved eight patients with relapsed/refractory multiple myeloma, showing that six achieved a partial response or better, with three achieving complete responses. The therapy demonstrated a manageable safety profile, with no severe cytokine release syndrome or neurotoxicity observed. The trial is in the dose-exploration phase, with plans for a Phase 1b registrational study in 2026.
Trendline Trendline
Gilead's Kite Unit Prepares Anito-cel Filing Following Promising iMMagine-1 Trial Results

Gilead's Kite Unit Prepares Anito-cel Filing Following Promising iMMagine-1 Trial Results

Gilead's Kite Unit Prepares Anito-cel Filing Following Promising iMMagine-1 Trial Results
Rapid Read Rapid Read
CARsgen Presents Promising Data for Allogeneic CAR-T Therapy CT0596 in Multiple Myeloma

CARsgen Presents Promising Data for Allogeneic CAR-T Therapy CT0596 in Multiple Myeloma

CARsgen Therapeutics has announced clinical data from its allogeneic BCMA-targeted CAR-T therapy, CT0596, for relapsed/refractory multiple myeloma. Presented at the 2025 ASH Annual Meeting, the trial involved eight patients, with six achieving a partial response or better. The therapy demonstrated a manageable safety profile, with no severe adverse events reported. CT0596 is developed using CARsgen's THANK-u Plus platform and is being evaluated for other plasma cell malignancies and autoimmune diseases. The company plans to initiate a Phase 1b registrational study in 2026.
Rapid Read Rapid Read
AstraZeneca's Dual-Target CAR-T Therapy Shows Promise in Multiple Myeloma

AstraZeneca's Dual-Target CAR-T Therapy Shows Promise in Multiple Myeloma

AstraZeneca has reported promising results from its dual-target CAR-T therapy, AZD0120, for treating multiple myeloma. The therapy, which targets both BCMA and CD19, demonstrated a high objective response rate of 96% in a phase 1b/2 trial. The study, conducted in the U.S., showed that AZD0120 was well-tolerated, with no severe adverse events reported. The therapy is based on Gracell's FasTCAR platform, allowing for rapid manufacturing. These results were presented at the American Society of Hematology congress, highlighting the potential of AZD0120 as an effective treatment option.
Trendline Trendline
Kite Announces Promising Data for Anito-cel in Multiple Myeloma Patients

Kite Announces Promising Data for Anito-cel in Multiple Myeloma Patients

Kite Announces Promising Data for Anito-cel in Multiple Myeloma Patients
Rapid Read Rapid Read
Kite's iMMagine-1 Study Shows Promising Results for Anito-cel in Multiple Myeloma

Kite's iMMagine-1 Study Shows Promising Results for Anito-cel in Multiple Myeloma

Kite, a Gilead Company, has announced positive data from its iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma. The study, presented at the 67th American Society of Hematology Annual Meeting, reported a 96% overall response rate and a 74% stringent complete response rate among 117 patients. The safety profile was manageable, with no delayed neurotoxicities observed. Anito-cel, a BCMA-directed CAR T-cell therapy, is being developed in collaboration with Arcellx and is expected to launch in the U.S. in 2026. The therapy has shown deep and durable efficacy, with a predictable safety profile, making it a potential new treatment option for multiple myeloma patients.
Trendline Trendline
Regeneron Advances Lynozyfic for Untreated Multiple Myeloma with Promising Study Results

Regeneron Advances Lynozyfic for Untreated Multiple Myeloma with Promising Study Results

Regeneron Advances Lynozyfic for Untreated Multiple Myeloma with Promising Study Results
Rapid Read Rapid Read
Gallop Oncology Reports Promising Phase 1b Trial Results for LYT-200 in AML and MDS Patients

Gallop Oncology Reports Promising Phase 1b Trial Results for LYT-200 in AML and MDS Patients

Gallop Oncology, a company founded by PureTech Health, has announced positive initial results from a Phase 1b clinical trial of LYT-200, a monoclonal antibody, in patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The trial demonstrated favorable tolerability and strong efficacy, with an initial median overall survival of 13.2 months in the combination cohort, significantly exceeding the expected survival of less than 2.5 months in similar settings. The trial included patients with high-risk mutations, indicating potential broad applicability of LYT-200. The findings support the advancement of LYT-200 into a potentially registrational Phase 2 trial, with further details to be shared at the upcoming American Society of Hematology Annual Meeting.
Rapid Read Rapid Read
AstraZeneca's CAR-T Therapy AZD0120 Shows High Efficacy in Multiple Myeloma Trials

AstraZeneca's CAR-T Therapy AZD0120 Shows High Efficacy in Multiple Myeloma Trials

AstraZeneca has reported promising results from its phase 1b/2 DURGA-1 trial of AZD0120, a dual BCMA and CD19-directed CAR-T therapy for relapsed/refractory multiple myeloma. The trial, conducted in the US, showed an objective response rate of 96% and a complete response rate of 78.3%. The therapy was well-tolerated, with no severe adverse events, and is suitable for outpatient administration. AZD0120 is based on Gracell's FasTCAR platform, allowing for rapid manufacturing. The therapy is also being tested for other conditions, including systemic lupus erythematosus and amyloid light chain amyloidosis.
Rapid Read Rapid Read
Aleta Biotherapeutics and Cancer Research UK Report Promising Results in B-Cell Malignancy Trial

Aleta Biotherapeutics and Cancer Research UK Report Promising Results in B-Cell Malignancy Trial

Aleta Biotherapeutics, in collaboration with Cancer Research UK's Centre for Drug Development, has announced promising results from a phase I/II clinical trial of their CAR T-cell engager biologic, ALETA-001. The trial targets patients with B-cell malignancies who have previously undergone anti-CD19 CAR T-cell therapy. The study, conducted across multiple sites in the UK, aims to evaluate the safety and efficacy of ALETA-001. Preliminary findings indicate a highly tolerable safety profile and encouraging efficacy responses in patients with refractory or relapsed disease. The trial involves dose escalation to determine the optimal dose for further study. The results suggest that ALETA-001 can enhance the effectiveness of existing CAR T-cell therapies by increasing CD19 antigen density, potentially offering a new therapeutic option for patients who relapse after initial CAR T-cell treatment.
Trendline Trendline
Gallop Oncology Reports Promising Phase 1b Trial Results for LYT-200 in Acute Myeloid Leukemia

Gallop Oncology Reports Promising Phase 1b Trial Results for LYT-200 in Acute Myeloid Leukemia

Gallop Oncology Reports Promising Phase 1b Trial Results for LYT-200 in Acute Myeloid Leukemia